Johnson & Johnson on Wednesday proposed a plan to pay nearly $6.5 billion to resolve tens of thousands of lawsuits claiming that its cosmetic talc-based powder causes cancer. Through a ...
A subsidiary of Johnson & Johnson (J&J) is proposing to pay nearly $6.5 billion to resolve nearly all the talc ovarian cancer lawsuits brought against the company. J&J said the subsidiary plans to ...
May 1 (UPI) --Pharmaceutical giant Johnson & Johnson on Wednesday said it is taking steps to resolve a multibillion dollar, cancer-related lawsuit with thousands of individuals over claims that ...
Johnson and Johnson reiterated in its statement on Wednesday, May 1, that “none of the talc-related claims against it have merit” Charna Flam is a writer-reporter at PEOPLE. She has been ...
Johnson & Johnson has a multibillion-dollar problem with its talcum powder and it just admitted that the best solution is also a multibillion-dollar one. The pharmaceutical giant, J&J for short ...
Benzinga - by Vandana Singh, Benzinga Editor. Wednesday, Johnson & Johnson (NYSE:JNJ) announced its intention to proceed with a $6.475 billion settlement to resolve numerous lawsuits related to ...
A subsidiary of Johnson & Johnson is now proposing to pay approximately $6.48 billion over 25 years as part of a settlement in the U.S. to cover allegations that its baby powder containing talc ...
TAR-210 is an intravesical targeted releasing system designed to provide sustained, local release of erdafitinib into the bladder. TAR-210 is an intravesical targeted releasing system designed ...
Johnson & Johnson said Wednesday it has offered to pay $6.5 billion to settle allegations that its talc products caused cancer, a key step in the pharmaceutical giant potentially resolving decades ...
Johnson & Johnson Will Pay $6.5 Billion to Settle Talc Ovarian Cancer Lawsuits By Ernie Mundell HealthDay Reporter THURSDAY, May 2, 2024 (HealthDay News) -- Johnson & Johnson announced Wednesday ...
Benzinga - by Vandana Singh, Benzinga Editor. On Sunday, Johnson & Johnson (NYSE:JNJ) ) released updated results from an open-label, multicenter, multi-cohort Phase 1 study of TAR-210 in patients with ...
The deal is pending, requiring the approval of 75% of claimants THURSDAY, May 2, 2024 (HealthDay News) -- Johnson & Johnson announced Wednesday that it would pay out more than $6.5 billion over ...